DPI China| Strive for Ten Years, Keep the Original Heart: Suzhou Singmed Participated in the 10th DPI China Technology Conference
Following the great success of the first DPI China Conference in 2013, the 10th DPI China was held in Shanghai on March 30 and 31, 2023.
Led by Executive Director Mr. Albert Zhao, the Suzhou Singmed delegation attended the meeting to conduct in-depth discussions and interchanges with representatives from various sectors of the industry.
Conference Background
Due to the intensification of social urbanization, human respiratory diseases caused by serious air pollution have increased. At present, there are about 300 million Asthma patients worldwide, and nearly 45.7 million asthma patients in China, 70% of whom are undiagnosed and 95% are not regulated for treatment (Lancet, 2019). Chronic Obstructive Pulmonary Disease (COPD) is currently the fourth leading cause of death in the world. Epidemiological studies in China show that the prevalence of COPD in people over 40 years of age is 8.2%. The global Asthma/COPD therapeutics market is expected to reach $33 billion by 2027 and grow at a 6.5% CAGR (iHealthcareAnalyst, 2020).
Dry powder inhaler(DPI), refers to the preparation of solid micro-powdered raw materials, alone or mixed with suitable carriers, in the form of capsules, vesicles or multi-dose storage, using a special dry powder inhalation device, which is actively inhaled by patients into the lungs of atomized drugs. It has been studied abroad for decades, and most of the drugs on the market are for the treatment of asthma and chronic obstructive pulmonary disease.
The purpose of this conference is mainly to focus on the latest technology, market trends and domestic and foreign regulations of dry powder inhalation products and increase domestic and foreign technical exchanges.
At the conference, representatives of various enterprises in the industry discussed the safety performance considerations of DPI drugs themselves and related supporting facilities, technological research and development innovation, market trends, domestic and foreign regulatory requirements, and expressed their own opinions and suggestions.
During the meeting, Mr. Albert Zhao, founder and executive director of Singmed, shared the experience, inspiration and achievements of Singmed from its initial development to today's scale in the past few years - "The Best Practice of Inhalation Spray Device Development" :
The vision of Singmed is: using the technological innovation of Medical devices to empower the clinical efficacy of drug delivery and develop patient-centered drug-device combination products.
Singmed focuses on the three core drug delivery areas of pulmonary drug delivery, nasal drug delivery and ophthalmic drug delivery, concentrating on innovative design and manufacturing of drug delivery devices, so that optimized atomizing delivery can bring better drug treatment effects, provides customers with obvious clinical advantages of drug delivery device solutions, and utilizes drug delivery mechanism innovation to develop new combination products (improved new drugs), bringing patients a better life.
In the speech, Mr. Albert Zhao presented several of our outstanding products, including the new generation of inhalers for respiratory drugs - Soft Mist Inhaler (SMI). It’s advantage lies in：
· The pocket-sized device is designed to deliver a one-breath inhalable aerosol, aiming to optimize drug delivery efficiency to the lungs, minimize patient coordination and inspiratory force requirements, and enhance patient experience and convenience.
· Utilizing an innovative aerosol technology, this device converts a drug solution into a soft mist consisting of two rotating liquid jets that pass through each other via a precisely-designed two-channel nozzle. This unique soft mist exhibits characteristics such as low velocity, high cohesion, long residence time, and small particle size, which facilitate effective distribution of drugs in the lungs.
· SMI offers several advantages over other inhalers in terms of pulmonary deposition rate, oropharyngeal deposition rate, regional distribution, dose consistency, respiratory parameters, and patient satisfaction. By improving drug deposition in specific areas of the lungs like small airways, this device enhances treatment effectiveness while reducing potential side effects.
In addition, Mr. Albert Zhao also shared his insights on the production and development of DPI. He emphasized that scientific project management process is an inevitable condition for achieving excellent drug delivery device development results, there is no shortcut, and it is not only results-oriented, but the correct result incurred by scientific and rigorous research and development engineering management process. Enterprises should take the management of all stages of the project seriously and standardize all aspects from research and development to production. The manufacturing of SMI parts is the miracle of industry precision, there is no fast and economy, we must adhere to long-term doctrine and strengthen professionalism.
Nowadays, Singmed has broken through the technical barriers of several drug delivery devices, and conducted independent intellectual property research and development in the core technology areas of drug delivery system structure design, development and manufacturing of silicon based atomization chip, precision mold and automation, and has been providing innovative and generic drug device combination preparation market with integrated service solutions of structural design, patented FTO, tolerance analysis, medical materials, precision molds, process validation, precision injection molding, product validation and product assembly.
